根据特许权使用费购买协议，Royalty Pharma同意在交割时向卖方支付8.85亿美元首付款，向卖方购买 其就任何及所有包含单克隆抗体Imdelltra (tarlatamab)(包括任何剂量、形式(包括聚乙二醇化版本)、制剂 (无论短效还是长效)、给药方式或给药途径产品(合称Imdelltra产品)在中国以外地区年度销售的净收入 (Imdelltra中国外净收入)收取分级计算的中个位数百分比的特许权使用费的大部分权利。前述特许权使 用费系Amgen Inc.(安进)根据公司、卖方和安进于2019年10月31日签订并不时修订的合作协议(安进合作 协议)向卖方支付的费用。 此外，自交割至2026年8月25日，卖方有权自行决定向 Royalty Pharma出售额外的收取特许权使用费的 权利(卖出选择权)，行使卖出选择权可使卖方获得最高达6,500万美元的额外付款，该付款将根据额外的 特许权使用费的价值按比例进行调整。对于年度Imdelltra中国外净收入超过15亿美元的部分，卖方将分 享特许权使用费的一部分。除保留以上描述的收取特许权使用费的权利外，卖方还保留了安进合作协议 项下的其他经济利益。 百济神州( ...

根据特许权使用费购买协议，Royalty Pharma同意在交割时向卖方支付8.85亿美元首付款，向卖方购买 其就任何及所有包含单克隆抗体Imdelltra (tarlatamab)（包括任何剂量、形式（包括聚乙二醇化版本）、 制剂（无论短效还是长效）、给药方式或给药途径产品（合称Imdelltra产品）在中国以外地区年度销售 的净收入（Imdelltra中国外净收入）收取分级计算的中个位数百分比的特许权使用费的大部分权利。前 述特许权使用费系Amgen Inc.根据公司、卖方和安进于2019年10月31日签订并不时修订的合作协议向卖 方支付的费用。此外，自交割至2026年8月25日，卖方有权自行决定向Royalty Pharma出售额外的收取特 许权使用费的权利，行使卖出选择权可使卖方获得最高达6,500万美元的额外付款，该付款将根据额外 的特许权使用费的价值按比例进行调整。对于年度Imdelltra中国外净收入超过15亿美元的部分，卖方将 分享特许权使用费的一部分。除保留以上描述的收取特许权使用费的权利外，卖方还保留了安进合作协 议项下的其他经济利益。 格隆汇8月25日丨百济神州(06160.HK)公告， ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeOne Medicines Ltd. 百濟神州有限公司 （根據瑞士法律註冊成立的公司） （股份代號：06160） 內幕消息 百濟神州宣佈簽訂IMDELLTRA特許權使用費購買協議 本公告乃根據香港聯合交易所有限公司證券上市規則（「上市規則」）第13.09條及 根據證券及期貨條例（香港法例第571章）第XIVA部而刊發。 百濟神州有限公司（「本公司」或「百濟神州」）宣佈於2025年8月25日，本公司、本 公司的子公司BeOne Medicines I GmbH（「賣方」）與Royalty Pharma Investments 2023 ICAV（「Royalty Pharma」）（獨立第三方）簽訂了一份特許權使用費購買協議 （「特許權使用費購買協議」）。 根據特許權使用費購買協議，Royalty Pharma同意在交割時向賣方支付8.85億美 元首付款，向賣方購買其就任何及所有包含單克隆抗體Imdell ...

Core Viewpoint - The Chinese innovative drug industry is rapidly developing under policy support and globalization, with leading companies like BeiGene and HengRui Medicine making significant advancements through high R&D investments and dense pipelines [2][3]. Policy and Market Dynamics - The National Healthcare Security Administration initiated the 2025 medical insurance directory adjustment, emphasizing support for innovative drugs, which has boosted industry confidence [3]. - In the first half of 2025, the transaction amount for Chinese innovative drug BD reached $48.448 billion, highlighting accelerated globalization and international cooperation [3]. Company Performance Overview - **BeiGene**: Achieved revenue of 17.518 billion yuan, a 46% increase year-on-year, with a net profit of 450 million yuan, marking its first profitable half-year since listing. Its core product, Tislelizumab, generated sales of 2.643 billion yuan, up 20.6% [7]. - **HengRui Medicine**: Reported innovative drug sales and licensing income of 9.561 billion yuan, accounting for 60.66% of total revenue, with core innovative drug sales driving growth [8]. - **Hansoh Pharmaceutical**: Revenue reached 7.434 billion yuan, a 14.3% increase, with innovative drug sales contributing 82.7% [8]. - **Innovent Biologics**: Generated over 5.2 billion yuan in product revenue, a growth of over 35%, and completed a significant financing project [8]. - **China National Pharmaceutical Group**: Revenue of 17.57 billion yuan, with a net profit of 3.39 billion yuan, a 140.2% increase year-on-year [8]. - **East China Pharmaceutical**: Achieved revenue of 7.317 billion yuan, a 9.24% increase, with R&D investment rising significantly [9]. R&D Pipeline and Trends - The innovative drug sector is experiencing a concentrated R&D phase, with leading companies accelerating their pipeline development [10]. - **HengRui Medicine**: Six first-class innovative drugs were approved during the reporting period, with a robust pipeline including multiple drugs in various clinical stages [13]. - **BeiGene**: Continues to advance in ADC and bispecific antibodies, enhancing its international competitiveness [13]. - **Innovent Biologics**: Has 52 drugs in clinical stages, focusing on various innovative targets [13]. Role of Scientific Instrumentation - Scientific instrument manufacturers are transitioning from supporters to key enablers in the innovative drug sector, providing comprehensive technical support throughout the drug development process [3][14]. - **Waters Corporation**: Reported an 11% growth in pharmaceutical business, with a 70% increase in GLP-1 related income [15]. - **Agilent Technologies**: Increased revenue in life sciences and diagnostics, establishing strategic partnerships to enhance drug development capabilities [16]. - **Thermo Fisher Scientific**: Achieved $6 billion in laboratory product sales, exceeding market expectations, and providing comprehensive services for drug development [16]. Industry Outlook - The rapid development of new molecular types like antibodies and ADCs is creating significant challenges in quality management, fostering a deep coupling between innovative drug companies and scientific instrument manufacturers [18].

Core Insights - The article highlights the significant transformation occurring in China's biotechnology sector, driven by international investor interest and the competitive advantages of Chinese biotech companies [2][5]. Group 1: Investment Trends - Morgan Stanley has sponsored notable IPOs in the Hong Kong market, including projects from companies like Heng Rui Medicine and Ying En Biology, and has facilitated multiple refinancing projects totaling billions [1][3]. - The Hong Kong Stock Exchange has emerged as the world's second-largest biotechnology financing center, with 12 healthcare companies raising a total of $2.5 billion in the first half of 2025 [3]. - New listings have shown strong market performance, with an average first-day increase of 23.1% for the 12 healthcare companies [3]. Group 2: Financing Activities - Morgan Stanley has assisted Chinese issuers in raising over $5 billion in financing by the end of July, with notable projects including WuXi AppTec's $980 million share placement [4]. - The financing activities reflect a growing demand for biotech stocks, with significant oversubscription and reduced discount rates for recent offerings [4]. Group 3: Global Expansion of Chinese Biotech - Chinese biotech companies are increasingly pursuing international clinical registrations and market entries, with a notable rise in "License-out" agreements [5][6]. - The gap in innovation capabilities between Chinese and U.S. biotech firms has narrowed, with Chinese companies demonstrating significant advancements in drug development efficiency and cost [5][6]. - The total value of transactions related to antibody-drug conjugates (ADCs) has reached approximately $44 billion, indicating robust international collaboration [6]. Group 4: Strategic Collaborations - Chinese biotech firms are forming strategic partnerships with international giants, exemplified by Heng Rui Medicine's $12.5 billion deal with GlaxoSmithKline [6][7]. - The collaboration models are evolving from simple licensing to joint development and new company formations, showcasing increased confidence in Chinese biotech capabilities [6][7]. Group 5: Future Outlook and Challenges - The article emphasizes the need for Chinese biotech companies to overcome regulatory complexities and market entry barriers to enhance their global presence [8][9]. - Recommendations include building international talent teams, improving communication with regulatory bodies, and optimizing government support for innovation [9].

Group 1: Industry Overview - The report highlights the development of the biopharmaceutical industry in Beijing's Changping District, showcasing various enterprises and institutions involved in investment, research, and healthcare [1] - Changping District aims to create an ecosystem integrating investment, clinical applications, incubation, and industrial parks to promote the transformation of medical and health achievements [10][11] Group 2: Company Highlights - BeiGene is a global leader in cancer treatment innovation, focusing on developing innovative anti-tumor drugs, with a revenue of 17.5 billion RMB in the first half of 2025, representing a 46% year-on-year growth [3] - The company has over 30 potential drug candidates and has initiated more than 130 clinical trials across 45 countries/regions, with a significant number of projects showing "first-in-class" or "best-in-class" potential [3] - TUPAI Medical, established in 2017, is a leading provider of high-end ophthalmic medical equipment in China, with a research and development team comprising over 30% of its 400 employees and an annual R&D investment nearing 100 million RMB [3] Group 3: Collaborative Projects - The Beijing Flying Dart International Innovation Center, co-built by Chang Development Group, aims to meet international standards for biopharmaceutical R&D laboratories and provides comprehensive support for innovative enterprises [6][8] - The Life Valley International Precision Medicine Industrial Park, operated by Kangqiao Capital in collaboration with Chang Development Group, focuses on precision diagnostics and therapies, emphasizing cutting-edge technologies like cell therapy and AI healthcare [10] Group 4: Infrastructure and Ecosystem - The construction of the International Medical Device City, covering 1.28 million square meters, aims to create a comprehensive ecosystem for innovation in medical devices, facilitating the transition from laboratory results to clinical applications [13] - Chang Development Group has established a series of market-oriented sub-funds, with a total cooperation scale exceeding 21.7 billion RMB, investing in over 100 medical and health projects [10]

Core Viewpoint - The article highlights the expansion of various Chinese companies into international markets, showcasing their strategic moves and growth in overseas operations. Group 1: Company Expansions - Meituan's international delivery brand Keeta has launched in Doha, Qatar, with plans to expand into Brazil in the coming months [5] - Great Wall Motors has completed the construction of its factory in Brazil, with an annual production capacity of 50,000 vehicles [5][7] - Tea brand Cha Baidao has announced its first store in North America, located in New York, marking its entry into the U.S. market [5] - Lenovo is establishing a regional headquarters in Riyadh, Saudi Arabia, as part of its strategic expansion in the Middle East [6] Group 2: Financial Performance and Growth - Zero Run Auto reported its first half-year profit, with overseas markets becoming a significant growth driver, exporting 24,980 vehicles in the first seven months of 2025 [8] - Pop Mart plans to expand into emerging markets such as the Middle East and South Asia, expecting to exceed 200 overseas stores by the end of the year [8] - Xiaomi's automotive division aims for profitability in the second half of the year, maintaining its 2027 overseas expansion target [9] Group 3: New Business Models and Innovations - AliExpress has launched an "overseas hosting" model in Australia, following its success in other markets [5] - Yimutian, a major agricultural B2B platform, has gone public on NASDAQ, aiming to expand its offline services and international business [10] - Shouqu Technology has secured nearly 100 million yuan in angel funding to enhance its battery management systems and accelerate global market expansion [11] Group 4: Industry Trends - The global photovoltaic industry is witnessing increased competition, prompting Chinese companies to enhance their international presence and supply chain resilience [15] - The user-side energy storage market is recovering, with significant growth expected in commercial storage due to supportive policies and mature business models [14]

Company Developments - Meituan's international delivery brand Keeta has officially launched in Doha, Qatar, with plans to expand into more Gulf Cooperation Council (GCC) countries and enter the Brazilian market in a few months [2] - Great Wall Motors has completed the construction and production launch of its factory in Brazil, located in Iracemapolis, São Paulo, with an annual production capacity of 50,000 vehicles [2] - AliExpress has launched its "overseas hosting" model in Australia, following its implementation in several other countries including the US and Mexico [2] - Cha Bai Dao has announced the opening of its first North American store in New York, marking its entry into the US market, following successful expansions in Singapore and France [2] Strategic Expansion - Lenovo Group plans to establish a regional headquarters in Riyadh, Saudi Arabia, and has begun construction on a manufacturing facility expected to start trial production in 2026 [3] - MINISO's founder expressed intentions to expand the MINISO LAND stores overseas, emphasizing the importance of proprietary IP alongside global IP [3] - Leap Motor has achieved a milestone by reporting its first half-year profit, with overseas markets becoming a significant growth driver [3] - Pop Mart aims to expand into emerging markets such as the Middle East and South Asia, expecting to exceed 200 overseas stores by the end of the year [4] Financial Performance - Pop Mart reported a revenue of 13.88 billion yuan for the first half of 2025, a year-on-year increase of 204.4%, with adjusted net profit rising by 362.8% [4] - Xiaomi's automotive division is expected to start generating profits in the second half of the year, with plans to avoid price wars [4] - XGIMI's Vietnam factory has launched its first projector, with overseas revenue projected to reach 1.086 billion yuan in 2024, marking an 18.94% year-on-year increase [5] Market Trends - The user-side energy storage market is showing signs of recovery, with a focus on high-growth new markets and a concentration of market players [8] - Chinese innovative pharmaceutical companies are transitioning from followers to leaders in the market, with a focus on internationalization [8] - The global photovoltaic industry is experiencing increased competition, prompting Chinese companies to accelerate their global expansion efforts [9][10]

Investment Rating - The report assigns a "Buy-A" investment rating to the company, with a 6-month target price of 297.74 CNY [4][3]. Core Insights - The company's product revenue for the first half of 2025 reached 17.36 billion CNY, a year-on-year increase of 45.8%, while total revenue was 17.52 billion CNY, up 46.0% from the previous year [1]. - The net profit attributable to the parent company for the same period was 450 million CNY [1]. - The overseas market for the drug Zebutinib continues to expand, with Q2 2025 product revenue of 1.3 billion USD, a 42% year-on-year increase, driven primarily by sales growth in the US and Europe [1]. - Zebutinib sales in the US for Q2 were 684 million USD, up 43% year-on-year, while in Europe, sales reached 150 million USD, reflecting an 85% increase, attributed to market share gains across major European markets [1]. Financial Projections - Revenue projections for the company are estimated at 36.15 billion CNY, 45.94 billion CNY, and 55.64 billion CNY for 2025, 2026, and 2027 respectively, with net profits expected to be 1.20 billion CNY, 4.69 billion CNY, and 8.17 billion CNY for the same years [3][10]. - The report anticipates significant growth in the company's product pipeline, including the Bcl2 inhibitor Sotorasib and the BTK CDAC BGB-16673, with multiple key milestones expected in the second half of 2025 [2][3]. Market Performance - As of August 22, 2025, the company's stock price was 247.25 CNY, with a market capitalization of approximately 353.66 billion CNY [4]. - The stock has shown a 62% absolute return over the past 12 months, despite a relative decline of 1.8% over the past month [5].

Industry Trends - The Chinese innovative pharmaceutical industry is transitioning from "generic" to "innovation," with the proportion of FIC drugs increasing from 9% to 31% over the past decade, driven by policy reforms and increased R&D investment[2] - In the first half of 2024, China's cross-border e-commerce imports and exports reached approximately 1.32 trillion yuan, with a year-on-year growth of 5.7%, indicating significant industry resilience despite a slowdown in growth[10] - The global e-commerce sales are projected to reach $6.8 trillion by 2025, with Chinese cross-border e-commerce platforms rapidly expanding through innovative models[10] Market Opportunities - The Indonesian government has established a "negative investment list" that outlines sectors where foreign investment is restricted, including drugs, gambling, and high-risk mining activities, emphasizing the need for compliance with local regulations[2] - The Chinese hydrogen energy sector is accelerating its internationalization, with 44 overseas projects initiated this year, focusing on equipment exports and technology licensing[4] - The Chinese IP toy market is expected to grow significantly, with the market share of leading companies only at 20.8%, indicating opportunities for new entrants[8] Brand Dynamics - XGIMI Technology plans to issue H-shares for its Hong Kong listing, with overseas revenue increasing to 31.9%, highlighting the importance of global strategy amid domestic market challenges[12] - Luckin Coffee has entered the North American market with a competitive strategy against Starbucks, utilizing a digital operation model and aggressive pricing to attract consumers[12] - JD.com aims to acquire European electronics leader Ceconomy for €2.2 billion, marking a significant step in its internationalization strategy[13]